Roche’s Tecentriq failed a late-stage clinical trial in the form of urothelial cancer, the Swiss drug manufacturer stated Friday.
The study assessing Tecentriq as an after-surgery monotherapy didn’t meet its primary endpoint of disease-free survival compared to observation in individuals with muscle-invasive urothelial cancer.
Safety for Tecentriq appeared in step with the known security profile of the medication, and no new safety alerts had been identified.
“Decreasing the risk that muscle-invasive urothelial cancer will recur after a surgical procedure is very tough, and we’re disappointed that we weren’t able to considerably prolong illness-free survival,” stated Levi Garraway, chief medical officer.
She added, “We stay dedicated to exploring the potential benefits of immunotherapy for more individuals with early cancers.”
Tecentriq is already authorized in the U.S., EU, and different nations for treating numerous forms of non-small cell and small cell lung cancer, some sorts of metastatic urothelial carcinoma, and in PD-L1-optimistic metastatic triple-negative breast cancer.
Roche has active Phase III research for Tecentriq in early and bladder cancer, plus an intensive development program for the medication in a number of lung, genitourinary, skin, breast, gynecological, gastrointestinal, and head cancers.